Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents-Reference-Cited by-同舟云学术

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Published:2018-05-28 Issue:2 Volume:61 Page:319-332
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biom. J.

Author:

Jimenez Jose L.¹^ORCID,Tighiouart Mourad²,Gasparini Mauro¹^ORCID

Affiliation:

1. Politecnico di Torino; Dipartimento di Scienze Matematiche; Corso Duca degli Abruzzi, 24 10129 Turin Italy

2. Samuel Oschin Comprehensive Cancer Institute; Los Angeles CA 90048 USA

Funder

National Institutes of Health

National Center for Research Resources

H2020 Marie Skłodowska-Curie Actions

National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bimj.201700166/fullpdf

Reference25 articles.

1. Cancer phase i clinical trials: efficient dose escalation with overdose control;Babb;Statistics in Medicine,1998

2. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents;Braun;Biometrics,2010

3. A curve-free method for phase I clinical trials;Gasparini;Biometrics,2000

4. Phase I designs that allow for uncertainty in the attribution of adverse events;Iasonos;Journal of the Royal Statistical Society: Series C (Applied Statistics),2016

5. A two-dimensional search algorithm for dose-finding trials of two agents;Lee;Journal of Biopharmaceutical Statistics,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials;Biometrical Journal;2023-12-04

2. A Bayesian adaptive design for dual‐agent phase I–II oncology trials integrating efficacy data across stages;Biometrical Journal;2023-05-18

3. Combining Cytotoxic Agents with Continuous Dose Levels in Seamless Phase I-II Clinical Trials;Journal of the Royal Statistical Society Series C: Applied Statistics;2022-10-26

4. A nonparametric Bayesian method for dose finding in drug combinations cancer trials;Statistics in Medicine;2022-01-25

5. Bayesian Adaptive Designs for Phase I Trials;Principles and Practice of Clinical Trials;2022